Cycling peptides on and off
"Cycling" just means running a peptide for a defined stretch, then taking a break, rather than dosing forever. Here's why people do it, the patterns you'll actually see, and where the honest limits of the evidence are.
Why cycle at all
Two reasons come up most. The first is receptor desensitization: keep hammering a receptor and the response can dull over time, so a break is meant to keep it sensitive. The second is more philosophical for the growth-hormone peptides — the whole appeal of a sermorelin or ipamorelin is that it works with your body's natural pulses, and continuous dosing works against that logic. Cycling is an attempt to keep the system responsive rather than flatten it.
Worth saying plainly: cycling schedules are mostly clinical convention and user convention, not numbers that fell out of controlled trials. They're reasonable defaults, not proven optima.
The patterns you'll actually see
- Within-week cycling. The common one for growth-hormone secretagogues is five days on, two days off — a short weekly break meant to blunt desensitization while keeping a steady rhythm.
- Block cycling. Longer runs — think several weeks or a few months on, then a few weeks off — before repeating. Used when the goal builds over time, like body composition.
- Time-limited courses. The healing peptides (BPC-157, TB-500) are usually run as a defined course tied to an injury, not cycled indefinitely — you run it while healing, then stop.
- Acute, no cycling. Something like PT-141 is dosed for effect, not on a schedule, so "cycling" doesn't really apply.
What a break is actually for
The off-period isn't dead time — it's when you find out what the peptide was actually doing. If gains hold reasonably well through a break, that tells you something; if everything reverts immediately, that tells you something else. A washout is also the cleanest moment to reassess with your provider whether to continue, adjust, or stop.
The mistake to avoid
When results plateau, the instinct is to push the dose up or drop the breaks. That's usually the wrong move: a plateau is often just the shape of the curve (see what to expect), and climbing the dose mostly raises the risk profile without buying much. For the growth-hormone peptides in particular, chasing a higher dose means chasing a higher IGF-1, which is exactly the number you want to keep in a safe range.
Dose changes are a conversation with your prescriber, not a self-directed experiment.
Cycling and monitoring go together
Cycling only makes sense next to measurement. Set a baseline, track through the "on" block, and watch what the "off" block reveals — the mechanics of doing that well are in tracking results. For growth-hormone protocols, that includes periodic IGF-1 bloodwork so the breaks are guided by data, not guesswork.
For the receptor-level detail on why desensitization happens, the independent write-ups live on PeptideWellness.
This guide is educational and not medical advice, and nothing here is a dosing recommendation. Cycling and dose decisions belong with your prescriber. See our Medical Disclaimer.
Fuel your protocol with
the latest research + reviews
Independent updates on peptide therapy, breaking news from compounding pharmacies, and exclusive guides — straight to your inbox.
